

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Microba Life Sciences Limited</b>
<b>ABN</b>	82 617 096 652

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Mr Pasquale Rombola</b>
<b>Date of last notice</b>	<b>8 November 2022</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"> <li>Rombola Family Pty Ltd &lt;Rombola Family A/C&gt;. Pasquale Rombola is the sole director and sole shareholder of Rombola Family Pty Ltd and a beneficiary of the Rombola Family Trust</li> <li>Rombola Superannuation Pty Ltd &lt;Rombola Super Fund A/C&gt;. Pasquale Rombola is a director and a shareholder of Rombola Superannuation Pty Ltd and a beneficiary of the Rombola Super Fund.</li> </ol>
<b>Date of change</b>	25, 27 & 30 October 2023
<b>No. of securities held prior to change</b>	1. 5,200,000 Ordinary Shares 300,000 Options exercisable at \$0.675, expiring 29 April 2025.
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>400,000</li> <li>170,000</li> </ol>
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration includes brokerage/gst</b> Note: If consideration is non-cash, provide details and estimated valuation	\$128,830.22
<b>No. of securities held after change</b>	1. 5,600,000 Ordinary Shares 300,000 Options exercisable at \$0.675, expiring 29 April 2025. 2. 170,000 Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase of 170,000 shares for a total consideration of \$36,830.22 and the part take-up of 400,000 entitlement shares under the institutional component of the Entitlement Offer for a total consideration of \$92,000.00.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.